A transdermal skin-tightening composition acting on the deep supporting structure of the skin and its application

Abstract

This invention relates to a transdermal firming composition that acts on the deep supporting structure of the skin and its application. The invention discloses a composition containing Panax notoginseng extract, Saussurea involucrata extract, and a biotransformation complex, and its preparation method. The composition is obtained by homogenization, filtration, and freeze-drying of 20 parts Panax notoginseng extract, 15 parts Saussurea involucrata extract, and 45 parts biotransformation complex. This invention effectively degrades macromolecular substances in plant raw materials through a specific "enzyme-bacterial synergistic" biotransformation process, improving the release rate of active ingredients and skin permeability. This composition can be widely used in cosmetics with anti-aging and transdermal firming effects.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, and more particularly to a transdermal firming composition that acts on the deep supporting structure of the skin and its application. Background Technology

[0002] With the rapid development of the bio-cosmetics market, consumers' demands for skincare products have shifted from basic chemical synthesis to a pursuit of natural, safe, and highly effective plant-based active ingredients. Panax notoginseng and Saussurea involucrata, as traditional and precious plant resources in my country, are rich in active substances such as saponins, flavonoids, and polysaccharides. They have significant effects in anti-oxidation, anti-inflammation, promoting blood circulation, and skin repair, making them a hot topic in high-end cosmetics research and development.

[0003] However, traditional plant extraction processes have significant limitations. First, many large molecular components of plants (such as complex plant polysaccharides and large protein molecules) have difficulty penetrating the skin's stratum corneum barrier, resulting in low bioavailability. Second, simple physical combinations of plant components often fail to produce synergistic effects and may even lead to reduced activity due to interference between components. Furthermore, although Myrothamnus flabellifolia ("resurrection plant") and rye seed have excellent barrier repair and cell activation capabilities, their active substances are often encased within tough cell walls, making it difficult to fully release their core value using conventional extraction methods.

[0004] Bio-transformation technology, particularly through the synergistic effect of enzymatic hydrolysis and microbial fermentation, can transform macromolecules in plants into smaller, more easily absorbed active substances by the skin, generating new metabolic byproducts (such as organic acids and amino acids). Current bio-transformation processes often suffer from the following problems: incomplete transformation; single enzyme systems or single microbial strains often struggle to handle complex plant matrices; the transformed products are prone to inactivation or precipitation in complex cosmetic systems; and extracts struggle to form stable delivery structures in aqueous systems, affecting the final skin feel and efficacy of the product.

[0005] Therefore, developing a composition that can deeply integrate Panax notoginseng and snow lotus extracts, and process rye and Myrothamnus flabellifolia through a specific "enzyme-bacterial synergistic" biotransformation process to form a composition with high bioavailability and good micellarization characteristics, is of great scientific significance and commercial value for the development of a new generation of highly effective repair cosmetics. Summary of the Invention

[0006] The purpose of this invention is to overcome the shortcomings of the prior art and provide a transdermal firming composition that acts on the deep supporting structure of the skin and its application.

[0007] To achieve the above objectives, the technical solution adopted by the present invention is as follows: In a first aspect, the present invention provides a composition comprising the following components: Panax notoginseng extract, Saussurea involucrata extract, and a biotransformation complex, wherein the biotransformation complex is prepared by a biotransformation process from rye seed extract and Myrothamnus flabellifolia extract.

[0008] Further, by weight, the composition comprises 15-25 parts of Panax notoginseng extract, 10-20 parts of Saussurea involucrata extract, and 35-55 parts of biotransformation complex.

[0009] Furthermore, in the biotransformation complex, the original feed mass ratio of rye seed extract to Myrothamnus flabellifolia extract is (2-8):1.

[0010] Furthermore, in the biotransformation complex, the original feed mass ratio of rye seed extract to Myrothamnus flabellifolia extract is 4:1.

[0011] Furthermore, the biotransformation process is a combined process of directional enzymatic hydrolysis followed by synergistic fermentation.

[0012] Secondly, the present invention provides a method for preparing the aforementioned composition, characterized by comprising the following steps: S1, Preparation of biotransformation complex: Rye seed extract and Myrothamnus flabellifolia extract were mixed and subjected to biotransformation treatment to obtain biotransformation complex. S2, Mixed compound: The components obtained in S1 are mixed with the Panax notoginseng extract and snow lotus extract in proportion to their weight. S3, Homogenization: Stir and homogenize at 35-45°C for 20-40 minutes, then filter to obtain the composition.

[0013] Furthermore, the biotransformation treatment includes mixing rye seed extract and myrothamnus extract and adding purified water to prepare a matrix solution; adding a complex enzyme system and performing directional enzymatic hydrolysis at 40-55°C for 4-8 hours, followed by inactivation of the enzyme preparation by raising the temperature; then inoculating with bacterial strains for synergistic fermentation for 24-72 hours, centrifuging to collect the supernatant, and freeze-drying to prepare the biotransformation complex.

[0014] Furthermore, the complex enzyme system is a combination of cellulase, pectinase and acidic protease, with a mass ratio of (1-2): (1-2): (2-5); the strain is a mixed strain of Lactobacillus plantarum and Saccharomyces cerevisiae, with an inoculation ratio of (1-3):1.

[0015] Thirdly, the present invention provides the application of the aforementioned composition in the preparation of cosmetics, wherein the composition has a strengthening effect on the dermal-epidermal junction (DEJ) by increasing the expression of laminin-5 and type IV collagen, thereby improving the deep skin connection structure.

[0016] Fourthly, the present invention provides a cosmetic comprising the aforementioned composition, wherein the composition is added in the cosmetic at an amount of 0.1%-10% of the total mass, and the dosage form is selected from aqueous solutions, emulsions, creams, or serums (preferably 0.5%-5.0%, more preferably 1.5%-3.0%).

[0017] In this invention, the composition is applied to a liquid skincare product, and the formula is as follows: Ingredient name Dosage (%) The composition of the present invention 5.0 Sodium hyaluronate 0.5 glycerin 5.0 1,3-Butanediol 3.0 Polyglycerol-10 1.0 Phenoxyethanol / Ethylhexylglycerin 0.6 Deionized water Add to 100 In this invention, the composition can also be prepared into finished products such as freeze-dried powder, cream, and lotion.

[0018] In this invention, the cytotoxicity test is a commonly used biochemical experimental technique, which is a biochemical detection method used to measure cell activity, proliferation and toxicity. It is general knowledge for those skilled in the art. In short, mitochondrial dehydrogenases in living cells can reduce yellow MTT to water-insoluble purple crystalline formazan, while dead cells or metabolically inactive cells do not have this ability. The MTT reagent in this invention was purchased from Sangon Biotech.

[0019] In this invention, the BCA method is a commonly used biochemical experimental technique for determining the total protein concentration in solution, which is general knowledge for those skilled in the art. In short, the BCA method is mainly based on the biuret reaction and chelation colorimetric reaction. The BCA kit used in this invention was purchased from Solarbio Technology Co., Ltd.

[0020] In this invention, the detection of MMP-1 content, type IV collagen content, and laminin-5 content are all general knowledge for those skilled in the art. In short, the content of matrix metalloproteinase-1 (MMP-1) is commonly detected using enzyme-linked immunosorbent assay (ELISA), employing a double-antibody sandwich method. The capture antibody coated on the plate binds to MMP-1 in the sample, and then the enzyme-labeled detection antibody develops a colorimetric result, which is detected by OD at 450 nm. Quantitative analysis was performed on type IV collagen. The MMP-1 kit used in this invention was purchased from Jianglai Biotechnology Co., Ltd. (JL10180-96T). Furthermore, type IV collagen is a major structural component of the basement membrane, and its content is typically determined using a double-antibody sandwich assay. The type IV collagen detection kit used in this invention was purchased from Hengyuan Biotechnology Co., Ltd. (HB2372-Hu). Additionally, laminin-5, also known as Laminin-332, is a core component of the epithelial basement membrane and plays a crucial role in skin anchoring. Its detection method typically uses ELISA. The MMP-1 kit used in this invention was purchased from Renjie Biotechnology Co., Ltd. (RJ11992).

[0021] Compared with the prior art, the beneficial effects of the present invention are as follows: 1. This invention achieves deep micro-molecularization of active ingredients through a combined process of targeted enzymatic hydrolysis and synergistic fermentation. The synergistic effect of Panax notoginseng extract and Saussurea involucrata extract, under the action of a biotransformation complex, effectively activates fibroblast activity. Clinically, this results in a significant improvement in skin elasticity, overcoming the technical pain points of poor penetration and slow onset of action of traditional plant extracts. 2. The composition of the present invention can precisely target the DEJ structure. Through the active factors transformed from rye seed and Myrothamnus flabellifolia extract, it can precisely induce the expression of Laminin-5 and type IV collagen, thereby enhancing the connection between the epidermis and dermis. The increase in their content can significantly enhance the wavy fold structure (Rete Ridges) of the DEJ and prevent skin aging caused by basement membrane flattening. Detailed Implementation

[0022] To better illustrate the purpose, technical solution, and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0023] Unless otherwise specified, all other materials and reagents used in the examples are commercially available.

[0024] Example 1 One embodiment of the composition of the present invention includes Panax notoginseng extract, Saussurea involucrata extract and a biotransformation complex, wherein the biotransformation complex is prepared by a biotransformation process from rye seed extract and Myrothamnus flabellifolia extract; The method for preparing the composition of the present invention includes the following steps: S1, Preparation of biotransformation complex: Rye seed extract and Myrothamnus flabellifolia extract were mixed and subjected to biotransformation treatment to obtain biotransformation complex; wherein, the mass ratio of rye seed extract to Myrothamnus flabellifolia extract was 4:1. S2, Mixed compound: The compound component obtained in S1 is mixed with the Panax notoginseng extract component and the snow lotus extract component in a certain weight ratio; wherein, by weight, there are 20 parts of Panax notoginseng extract, 15 parts of snow lotus extract, and 45 parts of biotransformation complex. S3, Homogenization: Homogenize at 40°C and 4500 rpm for 30 minutes to fully micellize each component. Then filter through a 5.0 μm microporous nylon membrane and freeze-dry to obtain the composition.

[0025] The biotransformation process in step S1 includes: mixing rye seed extract and Myrothamnus flabellifolia extract and adding purified water (weight ratio 1:5) to prepare a matrix solution; adding a complex enzyme system and performing directional enzymatic hydrolysis at 45°C for 6 hours, then heating to 85°C for 20 minutes to inactivate the enzyme preparation; subsequently inoculating with bacterial strains for co-fermentation for 48 hours, centrifuging to collect the supernatant (centrifugation conditions: 8000 rpm, 30 minutes), and freeze-drying to prepare the biotransformation complex.

[0026] The complex enzyme system is a combination of cellulase, pectinase, and acidic protease in a mass ratio of 1:1:2.5; the bacterial strain is a mixture of *Lactobacillus plantarum* and *Saccharomyces cerevisiae*, with an inoculation ratio of 2:1, an inoculation mass of 2%, and an initial concentration of 1.0 × 10⁻⁶ for each bacterial culture. 7 CUF / mL.

[0027] To verify the effects of the biotransformation complex and its compatibility with plant extracts, the following groups (by weight) were set up, as shown in Table 1.

[0028] Table 1. Matching Groups Components Example 1 Comparative Example 1 Comparative Example 2 Comparative Example 3 Panax notoginseng extract 20 20 - 20 Snow lotus extract 15 15 - 15 Biotransformation complex 45 - 45 - Rye seed extract - - - 36 Myrothamnus flabellifolia extract - - - 9 purified water Add to 100 Add to 100 Add to 100 Add to 100 Note: The rye seed extract and myrothamnus extract in the table above are raw extracts that have not undergone biotransformation; the preparation method of the biotransformation complex is described in Example 1. Among them, the preservation number of Lactobacillus plantarum is GDMCC No. 62277; the preservation number of Saccharomyces cerevisiae is GDMCC No. 65310.

[0029] The only difference between Comparative Example 1 and Example 1 is that the biotransformation complex is not prepared, and the Panax notoginseng extract and Saussurea involucrata extract are compounded according to the weight parts before proceeding directly to step S3. The only difference between Comparative Example 2 and Example 1 is that after preparing the biotransformation complex by weight, step S3 is carried out directly. The only difference between Comparative Example 3 and Example 1 is that the biotransformation complex was not prepared. Instead, the extracts of Panax notoginseng, Saussurea involucrata, raw rye seed extract and Myrothamnus flabellifolia extract were compounded by weight and then step S3 was carried out directly.

[0030] Experimental effect test: Test Example 1: Cytotoxicity Assay Experimental system and sample size: Human immortalized keratinocytes were used, passaged at least twice, and then seeded into 96-well plates at a cell density of 5 × 10⁶ cells / well. 3 Each well was incubated at 37°C in 5% CO2 for 24 hours. The experimental groups are shown in Table 2 below.

[0031] Table 2 Grouping of Cytotoxicity Tests

[0032] Add the test samples to DMEM medium. Replace the normal control and blank control groups with fresh DMEM medium. Incubate at 37°C and 5% CO2 for 24 hours. After incubation, add MTT solution to each well according to the kit instructions and continue culturing for 4 hours. Remove the medium, add DMSO solution, vortex to mix, and measure the absorbance at 490 nm. The formula for determining cell viability is as follows: Cell viability (%) = (OD) 490样品组 -OD 490空白对照组 ) / (OD 490正常对照品组 -OD 490空白对照组 ) × 100% Among them, OD 490 This represents the absorbance value at 490 nm; Statistical results are expressed as mean ± SD. Statistical analysis was performed using GraphPad Prism software. ANOVA was used for statistical analysis in this experiment. The statistical results were analyzed with α = 0.05 as the critical value. p < 0.05 indicated a significant difference compared with the normal control group, and the cell viability was less than 100%, which was judged as cytotoxic. The detection results are shown in Table 3.

[0033] Table 3. MTT Test Results Group Detection concentration Cell vitality p-value Test results normal control group - 100±1.24 - Example 1 0.25% 101±1.61 >0.05 Non-cytotoxic 0.5% 100±2.13 >0.05 Non-cytotoxic 0.75% 98.6±1.93 >0.05 Non-cytotoxic 1.0% 85.4±1.84 <0.05 Cytotoxic Therefore, it can be concluded that the composition samples of the present invention have no obvious cytotoxicity in the concentration range of 0.75% (w / v).

[0034] Test Example 2: Elastase Inhibition Rate Experiment According to the principle of enzyme activity determination, the hydrolysis activity of elastase on the substrate Congo red-elastin was analyzed under the optimal conditions. The amount of pigment entering the hydrolysis solution was determined by colorimetry. The amount of enzyme required to hydrolyze 1 g of substrate in 120 min was defined as one elastase activity unit. An appropriate amount of elastase was weighed and added to the pH 8.8 boric acid buffer solution. After the enzyme was completely dissolved, the volume was fixed to contain 2.5 - 3.0 elastase activity units per milliliter.

[0035] The sample group, negative group, control group, and blank group were established respectively. After adding 0.05 mL of 0.75% test sample solution to each group, the sample group was added with 0.1 mL of 50 mM Tris-HCl buffer solution at pH 8.0 and 0.025 mL of 2.5 U / mL elastase. The negative group was added with 0.125 mL of 50 mM Tris-HCl buffer solution at pH 8.0. The control group was added with 0.125 mL of 50 mM Tris-HCl buffer solution at pH 8.0 and 0.025 mL of elastase solution. The blank group was added with 0.15 mL of 50 mM Tris-HCl buffer solution. After 20 min at 25 °C, 0.025 mL of 1 mM APPAN solution was added, and then after 20 min at 25 °C, the absorbance value was measured at a wavelength of 410 nm. Among them, the calculation formula for the elastase inhibition rate is as follows: Inhibition rate = [1 - (A1 - A2) / (B1 - B2)] × 100% Among them, A1 is the absorbance value of the test sample group, A2 is the absorbance value of the negative group, B1 is the absorbance value of the control group, and B2 is the absorbance value of the blank group.

[0036] The results are shown in Table 4.

[0037] Table 4 Elastase inhibition rate Sample Name unit result Example 1 % 81.15±2.11 Comparative Example 1 % 32.18±1.64 Comparative Example 2 % 40.24±2.15 Comparative Example 3 % 55.20±1.56 control group % 84.13±1.38 It can be seen from this that the inhibition rate of the sample in Example 1 is significantly higher than that in Comparative Example 1 or 2. Smaller molecular metabolites may be produced during the biotransformation process, and these products can more effectively competitively bind to the active site of elastase. The inhibition rate of the sample in Example 1 is much higher than the sum of those in Comparative Example 1 and Comparative Example 2, indicating that there is a significant synergistic effect between the biotransformation complex and the extracts of Panax notoginseng and Saussurea involucrata. In addition, the comprehensive inhibition rate of Comparative Example 3 is significantly lower than that of Example 1, indicating that the biotransformation complex has higher biological activity performance than simply stacking expensive natural plant extracts.

[0038] Example 2 After clarifying the synergistic effect, this example further optimized the effect of strain inoculation.

[0039] Preliminary experiments using cross-strike to verify the inhibition zone of the test strains at the intersection of streaks on petri dishes, and screening for strains without a clear band and exhibiting intertwined bacterial growth, resulted in the following final candidate strains: Three strains of Lactobacillus plantarum: A (GDMCC No. 62277), B (GDMCC No. 60455), and C (CCTCC M 2021080); Two strains of Saccharomyces cerevisiae: a (GDMCC No. 65310) and b (GDMCC No. 60692).

[0040] Orthogonal experimental design: An L9(34) orthogonal array was used for the comparative experiment, and the settings were as follows: Experimental Factor 1: Lactobacillus plantarum species L ( Lactobacillus (A, B, C) Experimental Factor 2: Type S of Saccharomyces cerevisiae (S) Saccharomyces (a, b) Experimental Factor 3: Inoculation ratio (1:1, 2:1, 4:1) The design groups are shown in Table 5 below.

[0041] Table 5 Orthogonal Experiment Grouping Group Experimental Factor 1 Experimental Factor 2 Experimental factor 3 (:) 1 A a 1：1 2 A a 2：1 3 A a 4：1 4 A b 1：1 5 A b 2：1 6 A b 4：1 7 B a 1：1 8 B a 2：1 9 B a 4：1 10 B b 1：1 11 B b 2：1 12 B b 4：1 13 C a 1：1 14 C a 2：1 15 C a 4：1 16 C b 1：1 17 C b 2：1 18 C b 4：1 control group / / / Test Example 3: Elastase Inhibition Rate Experiment The method is described in Test Example 2. In step S1, the total inoculation amount was 2% of the substrate mass, based on the total mass of the substrate solution (liquid mixture of rye seeds and myrothamnus flabellifolia). The results are shown in Table 6 below.

[0042] Table 6. Effects of different bacterial strain combinations and ratios on elastase inhibition rate. Group Elastase inhibition rate (%) 1 68.42±1.2 2 81.2±2.1 3 75.2±1.8 4 62.1±1.4 5 79.3±1.3 6 70.5±2.5 7 55.8±1.6 8 64.7±0.9 9 58.9±2.5 10 52.3±2.2 11 61.2±3.4 12 54.6±1.7 13 59.7±1.7 14 71.4±2.0 15 65.3±1.9 16 58.2±1.5 17 69.8±2.1 18 62.4±1.7 control group 32.5±2.3 Therefore, through horizontal comparison, it was found that the combination of *Lactobacillus plantarum* A and *Saccharomyces cerevisiae* a had a higher overall inhibition rate than other combinations, indicating that these two strains produced more efficient protease inhibitory active ingredients and released active substances during metabolism. Furthermore, when the ratio of the strains was 2:1, their symbiotic metabolism reached a balance, and the resulting metabolites had the strongest inhibitory effect on elastase. Compared with the control group, the fermented composition increased the elastase inhibition rate by nearly 2.5 times, fully demonstrating the core value of microbial synergistic fermentation in enhancing the anti-aging and firming effects of the composition.

[0043] Example 3 Enzymatic hydrolysis process Referring to Example 1, only the directional enzymatic hydrolysis process in step S1 is configured with variables, and the groups are set as shown in Table 7 below.

[0044] Table 7. Enzyme digestion test grouping Group Complex enzyme system (mass ratio) condition Enzymatic hydrolysis process Example 1 Cellulase:Pectinase:Acidic protease = 1:1:2.5 45℃，6h Complex enzyme system Comparative Example 4 Cellulase: Pectinase = 1:1 45℃，6h Deprived protease Comparative Example 5 acidic protease 45℃，6h Single enzyme system Comparative Example 6 / / Fermentation only Test Example 4: Determination of protein peptide content and elastase inhibition rate For the method of determining the elastase inhibition rate, please refer to Test Example 2; The method for determining the content of protein peptides is as follows: The peptide content in the enzymatic hydrolysate was determined using the BCA protein concentration assay kit (Solepro). The procedure was followed according to the instructions. The absorbance at A562nm was measured using an ELISA reader, and the peptide concentration was calculated based on the standard curve. The specific results are shown in Table 8.

[0045] Table 8. Determination of Enzymatic Hydrolysis Efficiency Group Protein peptide content (mg / g) Elastase inhibition rate (%) Result description Example 1 85.42±2.15 81.2±2.1 Full release of active ingredients Comparative Example 4 42.18±1.84 45.8±1.3 Reduced inhibition rate, lack of bioactive peptides Comparative Example 5 35.66±1.42 40.3±1.7 Insufficient cell wall disruption results in low extraction rate of active substances. Comparative Example 6 18.25±0.95 31.7±1.1 Insufficient activity conversion This indicates a significant positive correlation between protein and peptide content and elastase inhibition rate, suggesting that the small-molecule active peptides produced by acidic protease degradation can effectively achieve firming and anti-aging properties. Furthermore, increasing the acidic protease content increased the elastase inhibition rate from 45.8% to 81.2%, indicating that the cleavage of large-molecule proteins in rye seeds and Myrothamnus flabellifolia can more effectively inhibit elastase activity. Moreover, after digestion by cellulase and pectinase, the active ingredients can be effectively released from plant cells. In summary, this invention, through pretreatment with a specific ratio of complex enzymes, can deeply explore the bioactive potential of rye seeds and Myrothamnus flabellifolia, resulting in products that exhibit good effects in inhibiting elastic fiber degradation and maintaining skin elasticity.

[0046] Example 4: Targeted DEJ Repair Experiment After verifying the effects of the components and methods in Example 1 through the aforementioned embodiments and test examples, their targeted promotion effect on the DEJ structure was further verified. Specifically, HaCaT cell suspension was seeded into 96-well plates at a cell quantity of 5 × 10⁶ cells / well. 3 Each well was used to irradiate the model group and the sample group with UVB at an intensity of 20 mJ / cm². 2 (Among them, radiation dose (mJ / cm) 2 = Radiation intensity (mW / cm) 2 (×irradiation time), and then the sample group was added with serum-free DMEM diluted test sample (concentration of 0.75%) and cultured for 12 hours; the model group contained no sample, while the blank group was cultured in the same medium only. Each group was repeated 5 times. The cell supernatant of each group was collected, centrifuged at 3000 rpm for 20 min at 4℃, and the supernatant was collected. MMP-1, type IV collagen and laminin-5 were detected according to the ELISA kit instructions. One-way ANOVA was used for statistical analysis, and the results are shown in Table 9.

[0047] Table 9. Results of targeted DEJ repair experiments Group Processing conditions relative expression level of mmp-1 (%) Type IV collagen expression rate LN-5 expression rate Blank group / 100.0±2.8 100.0±3.5 100.0±2.9 Model group UVB 245.6±12.4# 52.4±4.1# 46.8±3.3# Sample group (Example 1) UVB+ 0.75% sample 118.2±8.6* 93.5±2.7* 89.6±3.1* Note: # Compared to the blank group, p <0.05; *Compared to the model group, p <0.05 The results showed that the composition of the present invention could inhibit the abnormal increase of MMP-1 caused by UVB and effectively prevent the excessive decomposition of collagen. In addition, when the composition of the present invention was added to the sample, the expression rate of damaged collagen returned to near normal, indicating that the composition could rebuild the structural support of the basement membrane band. The increase of LN-5 indicated that the adhesion of the DEJ structure was strengthened, which means that the composition of the present invention helps to improve skin-flesh separation and relaxation caused by aging.

[0048] The various embodiments described in this specification are presented in a progressive manner, with each embodiment focusing on its differences from other embodiments. Similar or identical parts between embodiments can be referred to interchangeably. The above description of the disclosed embodiments enables those skilled in the art to make or use the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. Therefore, the invention is not to be limited to the embodiments shown herein, but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A composition, characterized in that, It includes the following components: Panax notoginseng extract, Saussurea involucrata extract and biotransformation complex, wherein the biotransformation complex is prepared by biotransformation process from rye seed extract and Myrothamnus flabellifolia extract.

2. The composition according to claim 1, characterized in that, The composition comprises, by weight, 15-25 parts of Panax notoginseng extract, 10-20 parts of Saussurea involucrata extract, and 35-55 parts of biotransformation complex.

3. The composition according to claim 1, characterized in that, In the biotransformation complex, the original feed mass ratio of rye seed extract to Myrothamnus flabellifolia extract is (2-8):

1.

4. The composition according to claim 3, characterized in that, In the biotransformation complex, the original feed mass ratio of rye seed extract to Myrothamnus flabellifolia extract is 4:

1.

5. The composition according to claim 1, characterized in that, The biotransformation process is a combined process of directional enzymatic hydrolysis followed by synergistic fermentation.

6. A method for preparing the composition according to any one of claims 1-5, characterized in that, Includes the following steps: S1, Preparation of biotransformation complex: Rye seed extract and Myrothamnus flabellifolia extract were mixed and subjected to biotransformation treatment to obtain biotransformation complex. S2, Mixed compound: The components obtained in S1 are mixed with the Panax notoginseng extract and snow lotus extract in proportion to their weight. S3, Homogenization: Stir and homogenize at 35-45°C for 20-40 minutes, then filter to obtain the composition.

7. The preparation method according to claim 6, characterized in that, The biotransformation process includes mixing rye seed extract and myrothamnus extract and adding purified water to prepare a matrix solution; adding a complex enzyme system and performing directional enzymatic hydrolysis at 40-55°C for 4-8 hours, followed by inactivation of the enzyme preparation by raising the temperature; then inoculating with bacterial strains for synergistic fermentation for 24-72 hours, centrifuging to collect the supernatant, and freeze-drying to prepare the biotransformation complex.

8. The preparation method according to claim 7, characterized in that, The complex enzyme system is a combination of cellulase, pectinase and acidic protease, with a mass ratio of (1-2): (1-2): (2-5); the strain is a mixed strain of Lactobacillus plantarum and Saccharomyces cerevisiae, with an inoculation ratio of (1-3):

1.

9. The use of the composition according to any one of claims 1-5 in the preparation of cosmetics, characterized in that, The composition has a targeted strengthening effect on the dermal-epidermal junction (DEJ) by increasing the expression of laminin-5 and type IV collagen, thereby improving the deep skin connection structure.

10. A cosmetic comprising the composition according to any one of claims 1-5, characterized in that, The composition in the cosmetic is added in an amount of 0.1%-10% of the total mass, and the dosage form is selected from water, lotion, cream or serum.

Images